阿哌沙班用于血液透析房颤患者:多中心随机对照试验
RENAL-AF 试验为前瞻性随机开放标签盲法终点评价,纳入 154 例血液透析合并房颤且 CHA2DS2-VASc 评分≥2 的患者,随机接受阿哌沙班或剂量调整华法林。因入组困难提前终止,效力不足,无法就大出血或临床相关非大出血发生率得出比较结论;抗凝人群中临床相关出血事件约为卒中或系统性栓塞的 10 倍。
要点
- 阿哌沙班组与华法林组 1 年大出血或临床相关非大出血发生率分别为 32% 和 26%(HR 1.20,95%CI 0.63-2.30)。
- 1 年卒中或系统性栓塞发生率阿哌沙班组 3.0%,华法林组 3.3%。
- 死亡为最常见主要事件,阿哌沙班组 21 例(26%),华法林组 13 例(18%)。
核心结论
- 因效力不足,无法就阿哌沙班与华法林在血液透析房颤患者中大出血或临床相关非大出血发生率方面得出比较结论。
- 抗凝人群中临床相关出血事件约为卒中或系统性栓塞的 10 倍,提示需未来随机研究评估抗凝的风险获益。
研究设计与样本
- RENAL-AF 为前瞻性、随机、开放标签、盲法终点评价(PROBE)试验,比较阿哌沙班与华法林。
- 纳入接受血液透析的房颤且 CHA2DS2-VASc 评分≥2 的患者,随机 1:1 分配至阿哌沙班 5 mg 每日两次(≥80 岁或体重≤60 kg 者 2.5 mg 每日两次)或剂量调整华法林。
- 2017 年 1 月至 2019 年 1 月共随机 154 例患者(阿哌沙班 n=82,华法林 n=72),因入组困难提前终止。
主要发现
- 华法林组治疗范围内时间(INR 2.0-3.0)为 44%(四分位距 23%-59%)。
- 1 年大出血或临床相关非大出血发生率:阿哌沙班组 32%,华法林组 26%(HR 1.20,95%CI 0.63-2.30)。
- 1 年卒中或系统性栓塞发生率:阿哌沙班组 3.0%,华法林组 3.3%。
- 死亡为最常见主要事件:阿哌沙班组 21 例(26%),华法林组 13 例(18%)。
- 药代动力学亚组纳入目标 50 例;阿哌沙班 5 mg 每日两次的稳态 12 小时 AUC 中位数为 2475 ng/mL×h(第 10 至 90 百分位 1342-3285),2.5 mg 每日两次为 1269 ng/mL×h(第 10 至 90 百分位 615-1946)。
临床怎么用
- 现有数据不足以支持在血液透析房颤患者中常规优先选择阿哌沙班而非华法林。
- 应关注该人群抗凝出血风险显著高于血栓栓塞风险,个体化评估抗凝获益与风险。
局限性
- 试验因入组困难提前终止,效力不足,无法得出比较结论。
- 华法林组治疗范围内时间仅 44%(四分位距 23%-59%),可能影响比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are no randomized data evaluating the safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial fibrillation (AF). METHODS: The RENAL-AF trial (Renal Hemodialysis Patients Allocated Apixaban Versus Warfarin in Atrial Fibrillation) was a prospective, randomized, open-label, blinded-outcome evaluation (PROBE) of apixaban versus warfarin in patients receiving hemodialysis with AF and a CHA2DS2-VASc score ≥2. Patients were randomly assigned 1:1 to 5 mg of apixaban twice daily (2.5 mg twice daily for patients ≥80 years of age, weight ≤60 kg, or both) or dose-adjusted warfarin. The primary outcome was time to major or clinically relevant nonmajor bleeding. Secondary outcomes included stroke, mortality, and apixaban pharmacokinetics. Pharmacokinetic sampling was day 1, day 3, and month 1. RESULTS: From January 2017 through January 2019, 154 patients were randomly assigned to apixaban (n=82) or warfarin (n=72). The trial stopped prematurely because of enrollment challenges. Time in therapeutic range (international normalized ratio, 2.0-3.0) for warfarin-treated patients was 44% (interquartile range, 23%-59%). The 1-year rates for major or clinically relevant nonmajor bleeding were 32% and 26% in apixaban and warfarin groups, respectively (hazard ratio, 1.20 [95% CI, 0.63-2.30]), whereas 1-year rates for stroke or systemic embolism were 3.0% and 3.3% in apixaban and warfarin groups, respectively. Death was the most common major event in the apixaban (21 patients [26%]) and warfarin (13 patients [18%]) arms. The pharmacokinetic substudy enrolled the target 50 patients. Median steady-state 12-hour area under the curve was 2475 ng/mL×h (10th to 90th percentiles, 1342-3285) for 5 mg of apixaban twice daily and 1269 ng/mL×h (10th to 90th percentiles, 615-1946) for 2.5 mg of apixaban twice daily. There was substantial overlap between minimum apixaban blood concentration, 12-hour area under the curve, and maximum apixaban blood concentration for patients with and without a major or clinically relevant nonmajor bleeding event. CONCLUSIONS: There was inadequate power to draw any conclusion regarding rates of major or clinically relevant nonmajor bleeding comparing apixaban and warfarin in patients with AF and end-stage kidney disease on hemodialysis. Clinically relevant bleeding events were ≈10-fold more frequent than stroke or systemic embolism among this population on anticoagulation, highlighting the need for future randomized studies evaluating the risks versus benefits of anticoagulation among patients with AF and end-stage kidney disease on hemodialysis. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02942407.
引用
- Pokorney, Chertow, Al-Khalidi, et al. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation. 2022. PMID: 36335914. doi:10.1161/CIRCULATIONAHA.121.054990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。